Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study. (Q50501197)
Jump to navigation
Jump to search
scientific article published on 6 May 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study. |
scientific article published on 6 May 2016 |
Statements
Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study. (English)
1 reference
Marek Jutel
1 reference
Margitta Worm
1 reference
François Spertini
1 reference
Gilles DellaCorte
1 reference
Alexander Kettner
1 reference
Frédéric de Blay
1 reference
Lars Jacobsen
1 reference
Vincent Charlon
1 reference
Christophe Reymond
1 reference
6 May 2016
1 reference
138
1 reference
1
1 reference
162-168
1 reference